1/6. radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.Standard therapy for AIDS associated NHL (AANHL) is toxic and often ineffective. radioimmunotherapy (RIT) is an appealing alternative to chemotherapy because of the radiosensitivity of NHL and the ability of the Lym-1 monoclonal antibody to target therapeutic irradiation to NHL while relatively sparing normal tissue. A Phase I/II study of 90Y-2IT-BAD-Lym-1 was designed specifically for RIT of AANHL. The first patient has been treated with 15 mCi (7.5 mCi/m2) of 90Y-2IT-BAD-Lym-1, after an imaging dose of 111In-2IT-BAD-Lym-1. Before RIT, AANHL in the maxillary sinus extended into the oral cavity and axillary adenopathy was present. Imaging showed excellent accumulation of 111In-2IT-BAD-Lym-1 in the tumors. Substantial shrinkage of the oral lymphoma was observed 18 hours after the therapy dose of 90Y-2IT-BAD-Lym-1 and axillary adenopathy had disappeared by one week after RIT. Transient Grade IV myelosuppression was the only notable toxicity. Further RIT cycles were precluded by development of an antibody response (HAMA) against Lym-1. This novel preliminary study has shown that Lym-1 can target AANHL and produce significant tumor regression thereby providing encouragement to proceed with additional patients.- - - - - - - - - - ranking = 1keywords = cycle (Clic here for more details about this article) |
2/6. Successful treatment of aggressive HIV-associated non-Hodgkin's lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option.The incidence of non-Hodgkin's lymphoma (NHL) in individuals infected with human immunodeficiency virus (HIV) is more than 60 times higher than in matched controls. In the vast majority of cases aggressive pathological subtypes and advanced stages prevail, extranodal sites are involved and systemic symptoms are present. The prognosis of HIV-NHL remains poor and the optimal therapeutic approach has yet to be defined. We report a 48-year-old Ethiopian woman with advanced-stage HIV infection, who developed diffuse large cell, immunoblastic type B-cell NHL and was treated with a modified CHOP-like chemotherapy combined with Rituximab and supported with growth factor. Highly active antiretroviral therapy (HAART) and opportunistic infections prophylaxis were administered concomitantly. The patient completed 6 cycles of therapy and currently, 76 weeks after diagnosis, is in complete clinical remission. Despite the fact that there was a transient decrease in the CD4-positive cell number and a 1.5 log increase in plasma viral load there were no opportunistic infections, nor was life-threatening toxicity seen. Rituximab seems a well-tolerable and advantageous adjunct to chemotherapy and HAART in the treatment of aggressive HIV-associated NHL andshould be investigated in large trials in the future.- - - - - - - - - - ranking = 1keywords = cycle (Clic here for more details about this article) |
3/6. Primary B cell lymphoma of the rectum in a patient coinfected with hiv-1 and HTLV-I.This report describes a clinical case of a large cell, immunoblastic plasmacytoid malignant B-cell lymphoma of the rectum in an AIDS patient coinfected with HTLV-I. The malignant cells showed clonal genetic rearrangement of the HC (JH) and LCK genes. Infection by EBV was demonstrated serologically and with slot blots using genomic dna of the cancer cells. Southern blot analysis with dna extracted from the lymphoma cells were negative for HTLV-I. The patient received seven cycles of VACO-B which induced complete but transient clinical remission of the tumor. The final outcome of the patient is unknown.- - - - - - - - - - ranking = 1keywords = cycle (Clic here for more details about this article) |
4/6. Cardiac tumor as an initial manifestation of acquired immunodeficiency syndrome.A cardiac tumor was the first manifestation of acquired immunodeficiency syndrome (AIDS) in a female patient in a state of severe immunodeficiency caused by human immunodeficiency virus (HIV) infection. The extensive cardiac and extracardiac involvement shown by various imaging modalities, including echocardiography and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), suggested that she was in the critical stage of non-Hodgkin's lymphoma (NHL). AIDS was treated by highly active-antiretroviral therapy and the NHL was treated by a combination of rituximab-cyclophosphamide-vincristine-doxorubicine-predonisolone. After 6 cycles of chemotherapy, she was in complete remission. Her cardiac tumor dramatically reduced in size and FDG-PET showed no positive uptake on whole body imaging. Generally, an AIDS-related cardiac tumor tends to be diagnosed at the late stage of the disease because of its nonspecific clinical findings, resulting in an extremely poor prognosis. In the present case, the cardiac tumor was detected by echocardiography and treated with appropriate chemotherapy. early diagnosis and prompt treatment may improve a patient's prognosis.- - - - - - - - - - ranking = 1keywords = cycle (Clic here for more details about this article) |
5/6. Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma.BACKGROUND. Primary central nervous system lymphoma (PCNSL) is the most common brain tumor occurring in patients with acquired immune deficiency syndrome (AIDS). After diagnosis of PCNSL, the median survival time is 2-5 months with treatment with whole brain irradiation (WBI). methods. Four (of approximately 40) patients with AIDS and PCNSL seen by the University of california, San Diego (UCSD) Neuro-Oncology service were treated with multimodal therapy, including WBI with hydroxyurea, followed by 3 cycles of procarbazine/lomustine/vincristine (PCV) chemotherapy. RESULTS. survival after tumor diagnosis ranged from 11 to 16 months, with a median of 13.5 months. CONCLUSION. Selected patients with AIDS and PCNSL may have long survival when treated with multimodal therapy.- - - - - - - - - - ranking = 1keywords = cycle (Clic here for more details about this article) |
6/6. Combination of chemotherapy and antiviral therapy for Epstein-Barr virus-associated non-Hodgkin's lymphoma of high grade malignancy in cases of HIV infection.Two HIV patients with Epstein-Barr virus (EBV)-associated B cell lymphoma of high grade malignancy enjoyed prolonged remission after therapy with COPBLAM and the antiviral agent acyclovir. After 3, respectively 5 cycles of treatment, the patients (stage C3 according to CDC) responded to the administered drugs by achieving complete remission. Under maintenance therapy with acyclovir for 32, respectively 31 months, both patients still remain free of lymphoma as of today.- - - - - - - - - - ranking = 1keywords = cycle (Clic here for more details about this article) |